Key Decisions on Health Technology Assessment a...

By João L. Carapinha

August 19, 2025

Health technology assessment (HTA) plays a crucial role in determining whether new therapies are reimbursed within healthcare systems. At the July 18, 2025 meeting of the Adviescommissie Pakket (ACP), two high-profile orphan drugs—omaveloxolone (S...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Sanofi’s Rilzabrutinib Receives Orphan Designation for IgG4-Related Dis...
Most Expensive Drugs 2025: Trends and Implications in US Pharma Pricing
Efficacy of Ultomiris Pediatric TMA Treatment
Blinatumomab Benefit Assessment for ALL and Health Economics
Tolebrutinib MS Analysis: Evaluating Economic Impact in SPMS
Allopurinol Designated an Orphan Drug for Marfan Syndrome
NICE’s Approval of Marstacimab for Hemophilia B: Transforming Treatment...
High Orphan Drug Prices Persist Despite Market Exclusivity Expiration
ZEVASKYN Gene Therapy: A Breakthrough for Recessive Dystrophic Epidermolysis ...
Advancing Pediatric Leukemia Trial: Precision Medicine and Transformative Res...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...